Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan

Evaluating the Treatment Patterns in Men With Benign Prostatic Hypertrophy (Marketscan Database Study)

This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and delayed combination therapy. The MarketScan database will be utilized for this study (2000-2008)

Inclusion Criteria:

• Male
• aged 50 years or older
• a diagnostic claim for BPH
• at least one prescription claim for a 5ARI or AB in the enrollment period
• continuous eligibility for 6 months prior to and 12 months after index prescription date

Exclusion Criteria:

• diagnosis of prostate or bladder cancer during the study period
• any prostate-related surgical procedure within 1 month of the index prescription date
• prescription claim for finasteride 1 mg for male pattern baldness during the study period